Ever since ROS (reactive oxygen species) were shown to meet the criteria of true signalling molecules, such as regulated production and a specific biological function, many efforts have been made to understand the precise role of ROS. The function of ROS in pathological mechanisms is taking a more and more central role in various fields of biomedical research, including neurobiology, cardiology and cancer. An elevated oxidative status has been found in many types of cancer cells, and the introduction of chemical and enzymological antioxidants can inhibit tumour cell proliferation, pointing to a critical role of ROS in mediating loss of growth control. The present review describes ROS-regulated mechanisms that are associated with cancer and tumour invasiveness. The cellular processes that are linked to these ROS functions are mitogenic signalling and cell motility, while ROS have also been implicated in apoptosis and cellular senescence, two mechanisms regarded as being anti-tumorigenic. This 'two-faced' character of free radicals will be discussed and placed in the context of the physiological conditions of the tumour cell, the different molecular backgrounds, and the specific ROS. More detailed understanding of the signalling pathways regulated by ROS in tumour cells will open up new prospects for chemo-or gene-therapeutic interventions.
Introduction
ROS (reactive oxygen species) are implicated in a variety of different pathologies, such as diabetes and neurodegenerative diseases (e.g. Alzheimer's disease and Parkinson's disease). With regard to tumour development, ROS have been considered as DNA-damaging agents that increase the mutation rate and promote oncogenic transformation [1] . In contrast with these unspecifically acting cytotoxic ROS, free radicals produced in a regulated fashion are required participants in signalling pathways. The aim of the present review is to shed light on the essential role of ROS in influencing central cellular functions such as proliferation, cellular remodelling, apoptosis and senescence, that are implicated in the development of cancer and metastases. Advances in our understanding of the role of ROS as key molecules in signalling cascades might provide new opportunities for phar-
Role of ROS in cellular growth control and tumorigenesis
The first evidence for the biological significance of ROS production came from the observation that activated neutrophils use superoxide radicals as a defence mechanism against bacteria [2] , and that this oxidative burst is inducible by growth factors [3] . Many studies have now confirmed ROS production in non-phagocytic cells as a result of activated growth-receptor [RTKs (receptor tyrosine kinases)] signalling cascades, including activation by platelet-derived growth factor [4] , basic fibroblast growth factor [5] or epidermal growth factor [6] . In addition, cytokines such as tumour necrosis factor [5] , γ-interferon [7] and interleukins [8] are known ROS inducers. The response to mitogenic as well as to cytokine signals can be diminished by non-enzymic and enzymic antioxidants, which implies a direct role for ROS as second messenger molecules in transducing receptorinitiated signalling cascades that control diverse cellular events such as proliferation, apoptosis and inflammation [9] [10] [11] [12] . Upon growth factor stimulation, ROS act downstream of the RTKs and small GTP-binding proteins such as Ras and Rac, and upstream of members of the MAPK (mitogenactivated protein kinase) family. In transformed fibroblasts, Ras and Rac appear to be directly linked to the production of superoxide anions (O 2
•− ) and, in turn, transformation of the cells depends on this ROS formation, since it can be suppressed by treatment with antioxidants [10] . The outcome of ROS production in growth factor receptor signalling is the activation of downstream effector kinases of the MAPK family. Depending on the cellular system, different MAPK family members, such as p38 MAPK, ERK1 (extracellularsignal-regulated kinase 1) and JNK (c-Jun N-terminal kinase), have been shown to possess ROS-sensitive kinase activity [9, 13, 14] . The transduction signalling cascade elicited by ROS culminates in the activation of phosphorylation and transcriptional activation of c-Jun and c-Fos subunits of the active nuclear transcription factor AP-1 (activator protein-1), which in turn activates genes involved in cellular proliferation [5, 15, 16] .
Although the importance of ROS in transducing proliferative stimuli has become clearer in recent years, detailed mechanistic aspects of ROS signalling still have to be elucidated. One of the questions that remains is the nature of the enzymic machinery responsible for ROS production. First hints came from experiments with the flavoprotein inhibitor DPI (diphenylene iodonium), which has been shown to be a potent inhibitor of the O 2
•− -producing enzyme NADPH oxidase in bovine neutrophils [17] . Several studies have demonstrated that DPI, but not inhibitors of the superoxide-producing enzymes cytochrome P450, NO synthase or xanthine oxidase, can interfere with mitogenic stimulation of non-phagocytic cells [14, 18, 19] . The NADPH oxidase-catalysed ROS formation seems to encompass PI3-K (phosphoinositide 3-kinase) and the small Rho-GTPase Rac1, since the stimulation of hypertrophy in vascular smooth muscle cells by angiotensin II depends on the activity of both proteins [20] . Similar results were found for the production of H 2 O 2 in the hepatocarcinoma cell line HepG2 [21] . A homologue of the NADPH oxidase catalytic subunit gp91 phox of phagocytes, Nox1, has been cloned and was shown to be expressed in colon, prostate, uterus and vascular smooth muscle, but not in leucocytes. Interestingly, when overexpressed in NIH 3T3 mouse fibroblasts, Nox1 induces excessive production of ROS and a transformed phenotype with increased mitotic rates [22] . In summary, there is growing evidence for a central role for the PI3-K/Rac/ NADPH oxidase pathway in cellular transformation processes mediated by ROS. A present concept of how ROS are possibly generated within the cell and contribute to cellular signal transduction pathways is presented in Figure 1 .
In contrast with the role of ROS as mediators of cellular growth and potential oncogenic transformation, ROS have also been shown to be key regulators of mechanisms that preserve cellular homoeostasis, namely apoptosis, cell cycle arrest and cellular senescence. In apoptosis, ROS generation is generally attributed to the decrease in the mitochondrial membrane potential due to uncoupling of the electron transport chain. However, recent observations argue for participation of the Rac1/NADPH oxidase pathway in superoxide anion production in apoptosis [23] . Since many enzymic and chemical antioxidants abrogate the apoptotic response to different stimuli, ROS can be seen as an important mediator of programmed cell death [24] . The anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-xL have been shown to antagonize ROS production in apoptosis and to protect cells from exogenous oxidant-induced apoptosis [25, 26] . Nevertheless, a defined mechanistic model of how ROS are produced during apoptosis and how they contribute to the cascade of apoptotic events is still lacking. Further studies on the redox regulation of the pro-apoptotic Bax proteins and the BH3 (Bcl-2 homology domain 3)-only-subgroup, including Bid and Bad, will shed further light on the role of ROS in apoptotic processes.
Cellular senescence has been observed in response to constitutively active mitogenic signals [27] and, as participants in growth-related signalling, ROS are also linked to the development of a senescent phenotype. Sub-lethal doses of H 2 O 2 induce a senescent-like growth arrest in G 1 that is accompanied by the up-regulation of the tumour-suppressor p53 and its transcriptional target p21 [28] . Results from our group support the finding that elevated intracellular levels of H 2 O 2 due to stable overexpression of MnSOD (Mn superoxide dismutase) lead to a p21/p53-related cellular senescent phenotype. Interestingly, the overexpression of p21 induces, along with increased ROS levels, a cellular senescence phenotype that can be rescued by the antioxidant N-acetyl-L-cysteine [29] . PIG3 (p53-inducible gene 3), a protein with significant identity with oxidoreductases, has been suggested as a downstream mediator of the effects of p21 and p53 in oxidative stress [29, 30] . Therefore ROS are seemingly linked to key mediators of stress signalling cascades that can suppress cellular transformation by inducing cell cycle arrest, apoptosis and cellular senescence.
ROS as potential therapeutic targets in tumour therapy
A growing body of evidence suggests that elevated levels of ROS form a part of signalling cascades that induce and maintain the oncogenic phenotype of cancer cells. The finding that elimination of excessive ROS by chemical [31] or enzymic [32] antioxidants decreases the tumorigenicity of various types of tumour cells has opened up new areas for research in cancer biology. Members of the antioxidant defence system that have been used to suppress cell proliferation of transformed cells belong first of all to the O 2
•− -detoxifying SODs, such as Cu/ZnSOD and MnSOD, and to the group of peroxide-detoxifying enzymes, such as glutathione peroxidase and catalase. One of the most potent antioxidant enzymes with anti-tumour activity is the mitochondrial protein MnSOD. A large set of studies in different tumour cell lines has confirmed that overexpression of MnSOD leads to growth retardation [33] [34] [35] . However, the general perception of MnSOD as a tumour-suppressor protein is far from clearcut. Although MnSOD activity was found to be low in most cancers [36] , some investigators found high MnSOD expression to correlate with poor prognosis [37] , advanced stages of progression [38, 39] and an invasive and metastatic phenotype [40] . These data indicate that abnormally high levels of MnSOD activity, while suppressing cell growth, increase the invasive potential of cancer cells. A hint at a mechanistic model that explains the implication of MnSOD in cancer cell invasion came from the observation that overexpression of MnSOD results in the activation of enzymes of the zinc-dependent MMP (matrix metalloproteinase) family, namely MMP-1 [41] and MMP-2 [42] , that are implicated in cellular remodelling processes. The activation of MMPs is possibly based on transcriptional activation of the redox-sensitive transcription factor AP-1 and/or of nuclear factor-κB (NF-κB) by elevated H 2 O 2 levels induced by MnSOD activity: MMP-1, MMP-3 and MMP-9 exhibit several recognition sites for these transcription factors within their promoters [43, 44] . At least two members of the MMP family have so far been postulated to play a critical role in tumour invasion [45] , therefore supporting the hypothesis that the involvement of MnSOD in tumour invasiveness is based on induction of extracellular matrix remodelling by MMPs. In conclusion, an imbalance between superoxide anion production and hydrogen peroxide degradation occurring in cells overexpressing MnSOD might activate the metastatic potential of cancer cells. Nevertheless, it is not yet clear whether MnSOD is an inducer of the loss of matrix function in metastatic processes, or is simply up-regulated in response to this phenotype.
Recent data also point to a role for Rac1 in signal induction of motility and invasive properties of tumour cells in vitro by changing cell-cell and cell-matrix adhesions [46] . Indeed, the stimulation of vascular endothelial smooth muscle cells by vascular endothelial growth factor leads, dependent on Rac1 and NADPH oxidase, to the activation of MnSOD [19] , indicating the presence of a positivefeedback loop. Therefore, in Ras-transformed tumour cell types that exhibit permanent activation of the Ras/Rac pathway, MnSOD and Rac1 might co-operate in evading the matrix boundary and gaining invasive properties. Indeed, in the DNA-repair-deficient breast cancer cell line MCF-7, overexpression of MnSOD in the absence of an activated Ras/Rac pathway cannot induce invasiveness [47] . Better and specific understanding of the regulation of anti-proliferative pathways by MnSOD and its control of tumour invasion might aid in the design of novel therapies targeting the respective molecular pathways. In general, ROS appear to be key regulatory factors in molecular pathways linked to tumour development and tumour dissemination, which offer potential therapeutic invention points.
